Abstract | BACKGROUND: METHODS: A total of 60 SCLC patients with brain metastasis received a cycle of VPC regimen ( teniposide 60mg/m² iv on days 1-5, cisplatin 35mg/m² iv on days 1-3, semustine 80mg/m² PO on day 1) every 3-4 weeks. WBRT was administered on day 6 of the first cycle of chemotherapy at a dose of 2Gy given in 5 fractions per week. Patients with less than 3 brain lesions received WBRT at a dose of 30Gy and then small field radiotherapy up to total dose of 50Gy, otherwise they received WBRT at a total dose of 40Gy. Response was evaluated by brain and chest CT or MRI after WBRT and at least 2 cycles of chemotherapy were completed. RESULTS: All the patients completed WBRT combined with chemotherapy. Total response rate of primary pulmonary tumor was 46.7%, with 4 cases of CR. The objective brain response rate was 60.0%, with 11 cases of CR and 25 cases of PR. Symptom relief was observed in all 48 patients with neurological symptoms. Main adverse effects were myelotoxicity, nausea/ vomiting, constipation and alopecia. The follow-up rate was 93.3% with a median survival duration of 11.3 months. The 1-, 2- and 5-year survival rate was 43.3%, 35.0% and 6.7%, respectively. CONCLUSIONS:
Chemotherapy combined with WBRT can be safely performed for SCLC with brain metastasis and its short-term response is quite satisfactory. It may be worthy of further clinical investigation.
|
Authors | Wenwu Wang, Xuenong Ouyang, Yonghai Peng |
Journal | Zhongguo fei ai za zhi = Chinese journal of lung cancer
(Zhongguo Fei Ai Za Zhi)
Vol. 8
Issue 2
Pg. 136-8
(Apr 20 2005)
ISSN: 1009-3419 [Print] China |
PMID | 21189183
(Publication Type: English Abstract, Journal Article)
|